Interstitial nephritis associated with nivolumab in a patient with hodgkin lymphoma
Authors:
- Deivide de Sousa OliveiraDODeivide de Sousa Oliveira
- Juliene Lima MesquitaJMJuliene Lima Mesquita
- Yhasmine Delles Oliveira GarciaYGYhasmine Delles Oliveira Garcia
- Yensy Mariana Zelaya RosalesYRYensy Mariana Zelaya Rosales
- Romélia Pinheiro Gonçalves LemesRLRomélia Pinheiro Gonçalves Lemes
- Francisco Dário Rocha FilhoFFFrancisco Dário Rocha Filho
- Paula Frassinetti Castelo Branco Camurça FernandesPFPaula Frassinetti Castelo Branco Camurça Fernandes
- Pastora Maria Araujo DuartePDPastora Maria Araujo Duarte
- Maria da Silva PitombeiraMPMaria da Silva Pitombeira
- Fernando Barroso DuarteFDFernando Barroso Duarte
Open Access
- 1 July 2019
- journal article
- letter
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 65 (7) , 934-936
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Biomarkers for checkpoint inhibition in hematologic malignanciesSeminars in Cancer Biology, 2018
- Hodgkin lymphoma and PD-1 blockade: an unfinished storyAnnals of Lymphoma, 2017
- Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin LymphomaBlood, 2016
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialThe Lancet Oncology, 2016
- The future of immune checkpoint therapyScience, 2015